No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BIIB240712P232500
- 5.30
- +4.45+523.53%
15min DelayTrading Jul 12 13:05 ET
5.30High5.30Low
5.30Open0.85Pre Close5 Volume11 Open Interest232.50Strike Price2.65KTurnover0.00%IV-0.01%PremiumJul 12, 2024Expiry Date5.32Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma48.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease.The drug should be initiated in patients with mild cognitive
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler
Biogen Price Target Cut to $313.00/Share From $335.00 by Piper
Piper Sandler Maintains Overweight on Biogen, Lowers Price Target to $313
Piper Sandler analyst Christopher Raymond maintains Biogen with a Overweight and lowers the price target from $335 to $313.
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294
Express News | Biogen Inc : Piper Sandler Cuts Target Price to $313 From $335
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $313
Piper Sandler analyst Christopher Raymond maintains $Biogen(BIIB.US)$ with a buy rating, and adjusts the target price from $335 to $313.According to TipRanks data, the analyst has a success rate of 51
Comments
Keep an eye on these recently announced M&As: 👀
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co(MRK.US$ to acquire EyeBio
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Novartis AG(NVS.US$ to acquire Mariana Oncology
What companies will be next? 🤔
3
$Biogen(BIIB.US$ perhaps some puts on this 0.0
Keep an eye on these M&As: 👀
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Harmony Biosciences(HRMY.US$ acquired Epygenix Tx
What companies will be next? 🤔
$Biogen(BIIB.US$ to acquire HI-Bio™
$Johnson & Johnson(JNJ.US$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals(RPHM.US$
$Harmony Biosciences(HRMY.US$ acquired Epygenix Tx
What companies will be next? 🤔
7
$Biogen(BIIB.US$ 📣 Acquires Human Immunology Biosciences (HI-Bio)
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
4
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
Read more